How does resolution of inflammation work?
Resolution of inflammation is an active, programmed process driven by specialised pro-resolving mediators and host-directed enzyme control, not merely the passive fading of an immune response. This page summarises the la
Resolution of inflammation is the active, programmed termination of an inflammatory response, distinct from simple suppression or passive decay. It is driven by endogenous lipid mediators, by shifts in macrophage phenotype, and by the controlled degradation of tissue-damaging enzymes. The formal mediators most studied in this context are the specialised pro-resolving mediators (SPMs), a class of endogenous lipid-derived signalling molecules. The evidence block for this page does not supply a sequence, formula or molecular weight for any single SPM, so none is stated here. In the clinical literature the term is used operationally: resolution is measured as the acceleration of inflammatory clearance, suppression of tissue-damaging enzyme activity, and reduction of structural damage such as pulmonary cavity volume [4].
The pathway families the work centres on are the transforming growth factor-beta (TGF-beta) superfamily and its neutralisation by follistatin (FST), the matrix metalloproteinase (MMP) system and its tissue inhibitors (TIMPs), and the SPM signalling axis [1][3][4].
Research Studies
Follistatin and atherosclerotic lesion burden in mice
Follistatin binds to and neutralises members of the TGF-beta superfamily, regulating skeletal muscle, adipose and bone homeostasis. FST also promotes adipose browning and enhances energy metabolism, and has been reported to improve plasma lipid profiles and metabolic health in mice. Because brown adipose tissue (BAT) activation has been associated with reduced atherosclerosis, investigators examined the anti-atherogenic potential of FST. Transcriptomic and metabolomic analysis of the Hybrid Mouse Diversity Panel (HMDP) found that Fst expression was negatively correlated with aortic lesion area [1]. This finding is from a mouse panel; it does not establish the same relationship in humans.
Follistatin and arginine metabolism in adipose tissue
The same body of work links FST to activation of arginine metabolism alongside adipose browning. The evidence block describes the anti-atherogenic effect as operating through both arms, but does not report separate quantitative values for each arm, so no comparison table is presented for this pair [1].
Oral SPM supplementation and vascular ageing in obese hypertensive patients
A registered trial is examining the effect of oral SPM supplementation on inflammation-induced vascular ageing in obese hypertensive patients [2]. The rationale given is that cardiovascular risk factors including obesity, diabetes, high blood pressure, high cholesterol and smoking raise the risk of myocardial infarction, stroke and peripheral artery disease, and that a residual cardiovascular risk persists even under optimal treatment. That residual risk is attributed primarily to vascular lesions arising from inflammation, an activated immune state that is more pronounced in overweight individuals [2]. This is a clinical study in a defined patient population; results are not yet reported in the evidence block.
Doxycycline and matrix metalloproteinase balance in CNS tuberculosis
In central nervous system tuberculosis (CNS-TB), mortality under standard of care remains 30-50% even at tertiary centres. Standard management is anti-tuberculous therapy with adjunctive corticosteroids. In CNS-TB the activity of pathogenic host matrix metalloproteinases is unopposed to tissue inhibitors of metalloproteinases, producing a matrix-degrading phenotype that may drive worse outcomes. In a prior established CNS-TB murine model, the investigators demonstrated that adjunctive MMP inhibition using doxycycline [3]. The evidence block truncates at this point; the direction of the murine result is not stated in the supplied text, so it is not asserted here.
Doxycycline and resolution of inflammation in pulmonary tuberculosis
A recent Phase 2b double-blind randomised controlled trial reported that adjunctive doxycycline therapy is safe, accelerates resolution of inflammation, suppresses tissue-damaging enzyme activity and decreases pulmonary cavity volume [4]. This is the clearest direct clinical statement in the evidence block that resolution of inflammation can be accelerated pharmacologically. The population was patients receiving standard pulmonary TB treatment.
Doxycycline and post-tuberculosis lung impairment
Tuberculosis can cause chronic ill health after bacterial eradication, including pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease. A fully powered Phase III trial of 8 weeks of adjunctive doxycycline alongside standard pulmonary TB treatment is planned to determine whether it can reduce PIAT and improve cardiovascular outcomes [4].
Comparison of the two doxycycline trial settings
| Setting | Population | Phase | Reported status in evidence |
|---|---|---|---|
| Pulmonary TB | Patients on standard PTB treatment | Phase 2b completed; Phase III planned | Safe; accelerated resolution of inflammation; suppressed tissue-damaging enzyme activity; decreased cavity volume [4] |
| CNS-TB | CNS-TB patients; prior murine model | Adjunctive doxycycline study | Murine MMP inhibition demonstrated; outcome direction not stated in supplied text [3] |
Dental pulp stem cells and plaque biofilm-associated infection
A structured narrative review covering 2000-2025 synthesised evidence on the antimicrobial, immunomodulatory and regenerative properties of dental pulp stem cells in plaque-induced gingivitis and oral biofilm infections [5]. This is a review of immunomodulatory mechanisms rather than a resolution trial, and it supports the broader point that resolution involves active host cell programmes rather than passive decay.
Recombinant Klotho and sterile inflammation after haemorrhagic shock
Haemorrhagic shock produces systemic hypoperfusion with inflammatory responses, oxidative stress and apoptosis, often leading to multiple organ failure. Klotho, described as an antiaging protein with anti-inflammatory, antiapoptotic and antioxidative properties, has been studied in this setting [6]. The evidence block truncates before the result is stated, so no outcome is reported here.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Nothing here is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning. https://pubmed.ncbi.nlm.nih.gov/42439678/
- [2] The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients. https://clinicaltrials.gov/study/NCT07038252
- [3] Adjunctive Doxycycline for Central Nervous System Tuberculosis. https://clinicaltrials.gov/study/NCT06446245
- [4] Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis. https://clinicaltrials.gov/study/NCT05473520
- [5] Dental Pulp Stem Cells for the Management of Plaque Biofilm-Associated Infections: A Review. https://europepmc.org/article/PMC/PMC13140043
- [6] Recombinant Klotho Protein Protects Tissues by Mitigating the Detrimental Effects of Sterile Inflammation After Hemorrhagic Shock. https://europepmc.org/article/PMC/PMC13313470